U.K. NRT Harm Reduction Indication Could Be Model For U.S.

The U.K.'s harm reduction indication for a nonprescription nicotine replacement therapy inhaler could bode well for GlaxoSmithKline's request that FDA allow a similar change for NRT products in the U.S

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet